Overview

A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)

Status:
Recruiting

Trial end date:
2024-02-19

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to evaluate the antitumor activity and safety of Lenvatinib (MK-7902/E7080) in children, adolescents, and young adults with relapsed or refractory solid malignancies after administration. Participants will be enrolled into initial tumor-specific cohorts which will be expanded based on observed response.

Phase:

Phase 2

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Collaborator:

Eisai Inc.

Treatments:

Lenvatinib